In December 2025 the FDA approved the first oral weight-loss GLP-1: oral Wegovy (semaglutide 25 mg), and it landed at 13.6% average weight loss in the OASIS 4 trial — close to the 14.9% of the injection. But there is a catch that changes your whole morning: the pill must be taken fasting, with minimal water, and you cannot eat or drink for 30 minutes after.
| A | B | |
|---|---|---|
| Form | Weekly injection | Daily pill |
| Average weight loss | 14.9% (STEP 1) | 13.6% (OASIS 4) |
| Dosing ritual | Once a week | Every morning, fasting |
| Food timing rule | None hard-coded | 30 min fast after taking |
| Convenience | Needle + storage | Pill, but strict timing |
The same judgment framework runs across this site — protein, fiber and how heavy a food sits on a slow stomach.
| Easy on both | Risky on both |
|---|---|
|
|
Not for 30 minutes — the label is specific. Water is limited to a small amount with the pill, then nothing by mouth for half an hour. After that, a protein-first breakfast is a good plan.
Close. OASIS 4 showed 13.6% average weight loss versus 14.9% for the injection — a small gap, and some people who took the pill consistently did better (up to 16.6%).
Same food framework as the injection. The only new thing is the daily timing: the empty-stomach rule makes your breakfast schedule part of the medication routine.
This comparison presents published trial data (STEP, SURMOUNT, SCALE, OASIS 4) and FDA label information for reference. It is not medical advice and does not recommend any medication. Prescription decisions belong to you and your healthcare provider.